Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
This is a phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer.
Breast Cancer
DRUG: Standard cyclophosphamide|DRUG: Goserelin (Zoladex)
The study is to compare the rate of premature ovarian failure at two years following standard adjuvant or neoadjuvant chemotherapy, Three years
This is a phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer.